In this issue:
Comorbidity development in children with psoriasis
Guselkumab after inadequate response to ustekinumab
10 years of biological treatment for psoriasis
Extension of ustekinumab maintenance dosing interval
Th17 inhibitors in active psoriatic arthritis
Blood proteins after tofacitinib and etanercept
Effect of biologic therapy on depression
Psychiatric adverse events during brodalumab treatment
Ixekizumab effect on facial psoriasis and related quality of life
TNF inhibitor therapy and myocardial infarction incidence
Management of psoriasis in patients with IBD
Please login below to download this issue (PDF)